argenx surges to 291st in daily rankings with 3.02 billion trading volume despite 6.33% stock price drop

On May 6, 2025, argenx (ARGX) experienced a significant trading volume of 3.02 billion, marking an 118.66% increase from the previous day. This surge placed argenx at the 291st position in the daily stock market rankings. However, despite the high trading volume, the stock price of argenx declined by 6.33%.

argenx, a global immunology company, is set to present at the BofA Securities 2025 Health Care Conference on May 13, 2025. The company's CEO, Tim Van Hauwermeiren, along with other members of the management team, will deliver a presentation at 4:20 p.m. PT. This event provides an opportunity for argenx to showcase its advancements in the field of immunology and its commitment to developing novel antibody-based medicines for severe autoimmune diseases.

argenx has developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker, which has shown promise in treating multiple serious autoimmune diseases. The company is also evaluating the broad potential of this blocker in various therapeutic areas. Additionally, argenx is advancing several earlier-stage experimental medicines within its therapeutic franchises, further solidifying its position as a leader in immunology research and development.